Biochemical Characteristics of Dysfunctional Fibrinogen Found in Korea

Inho Kim; Seonyang Park; Soomee Kwon; Insook Chung; Sangyoon Lee

doi:10.5045/kjh.2005.40.1.34

Journal List > Korean J Hematol > v.40(1) > 1032647

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Park, Kwon, Chung, and Lee: Biochemical Characteristics of Dysfunctional Fibrinogen Found in Korea

Original Article

Korean J Hematol 2005;40(1):34-40.

Published online: 21 March 2005

DOI: https://doi.org/10.5045/kjh.2005.40.1.34

Biochemical Characteristics of Dysfunctional Fibrinogen Found in Korea

Inho Kim, M.D., Seonyang Park, M.D., Soomee Kwon, Insook Chung, Sangyoon Lee, M.D.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Correspondence to: Seonyang Park Department of Internal Medicine, Seoul National University College of Medicine 28 Yeongeon-dong, Jongno-gu, Seoul 110-744, Korea Tel: +82-2-2072-3347, Fax: +82-2-744-6075 E-mail: seonpark@plaza.snu.ac.kr

Received 31 January 2005 Revised 2 March 2005 Accepted 9 March 2005

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Hereditary dysfibrinogenemia is a rare cause of venous thromboembolism. Hereditary thrombophilia is diagnosed in about 10% of patients with thromboembolism, with the prevalence diagnosed increasing with the development of molecular biological method.

Methods

A 27-year-old woman was strongly suspected to have hereditary dysfibrinogenemia; therfore, an analysis of the molecular structure of the purified fibrinogen was performed.

Results

An SDS-PAGE analysis of the purified fibrinogen revealed no abnormal finding. The purified fibrinogen was treated with thrombin or coagulation factor XIII, and the products show no difference between the normal and patient's specimen on SDS-PAGE analysis. However, an HPLC analysis showed an additional abnormal peak prior to the normal fibrinopeptid A peak.

Conclusion

A dysfunctional fibrinogen showing an abnormal peak on HPLC analysis was detected in a Korean patient. Her family also showed dysfunctional fibrinogen. In a Korean patient with recurrent thromboembolism, hereditary dysfibrinogenemia should also be taken into consideration.

Keywords: Dysfunctional fibrinogen, Biochemical characteristics

REFERENCES

1). Malm J, Laurell M, Nilsson IM, Dahlback B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb Haemost. 1992; 68:7–13.

2). Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost. 1999; 25:311–9.

3). Mosesson MW. Hereditary abnormalities of fibrinogen. Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams hematology. 6th ed.New York: McGraw-Hill Co;2006. p. 1659–71.

4). Terukina S, Yamazumi K, Okamoto K, Yamashita H, Ito Y, Matsuda M. Fibrinogen Kyoto III: a congenital dysfibrinogen with a gamma aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood. 1989; 74:2681–7.

5). Miyata T, Furukawa K, Iwanaga S, Takamatsu J, Saito H. Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the gamma-chain that impairs the polymerization of fibrin monomer. J Biochem (Tokyo). 1989; 105:10–4.

6). Yoshida N, Hirata H, Morigami Y, et al. Characterization of an abnormal fibrinogen Osaka V with the replacement of gamma-arginine 375 by glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis. J Biol Chem. 1992; 267:2753–9.

7). Matsuda M, Baba M, Morimoto K, Nakamikawa C. “Fibrinogen Tokyo II”. An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest. 1983; 72:1034–41.

8). Matsuda M, Saeki E, Kasamatsu A, Nakamikawa C, Manabe S, Samejima Y. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A. Thromb Res. 1985; 37:379–90.

9). Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002; 126:499–505.

10). Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 1970; 227:680–5.

11). Francis CW, Marder VJ, Martin SE. Detection of circulating crosslinked fibrin derivatives by a heat extraction-SDS gradient gel electrophoretic technique. Blood. 1979; 54:1282–95.

12). Vanfleteren JR, Raymackers JG, Van Bun SM, Me-heus LA. Peptide mapping and microsequencing of proteins separated by SDS-PAGE after limited in situ acid hydrolysis. Biotechniques. 1992; 12:550–2. 554, 556-7.

13). Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on fibrinogen. Thromb Haemost. 1995; 73:151–61.

14). Brenner B. Inherited thrombophilia and fetal loss. Curr Opin in Hematol. 2000; 7:290–5.

15). Matsuda M. Structure and function of fibrinogen inferred from hereditary dysfibrinogens. Int J Hematol. 2000; 72:436–47.

16). Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acid Aα461-610. Blood. 1992; 80:1972–9.

17). Soria J, Soria C, Hedner U, Nilsson IM, Bergqvist D, Samama M. Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrino genemia (fibrinogen Malmoe). Br J Haematol. 1985; 61:727–38.

18). Nilsson IM, Nilehn JE, Cronberg S. Hypofibrinogenemia and massive thrombosis. Acta Med Scand. 1966; 180:65–76.

19). Ness PM, Budzynski AZ, Olexa SA, Rodvien R. Congenital hypofibrinogenemia and recurrent placental abruption. Obstet Gynecol. 1983; 61:519–23.

20). Loreth RM, Meyer M, Albert FW. Fibrinogen Kai-serslauten III: a new case of congenital dysfibrinogenemia with A alpha 16 arg→cys substitution. Haemostasis. 2001; 31:12–7.

21). Mathonnet F, Peltier JY, Roda L, et al. Three new cases of dysfibrinogenemia: Poissy III, Saint-Germain I and Tahiti. Thromb Res. 2001; 103:201–7.

22). Lounes KC, Soria C, Mirshahi SS, et al. Fibrinogen Ales: a homozygous case of dysfibrinogenemia (gamma-Asp (330)→Val) characterized by a defective fibrin polymerization site a. Blood. 2000; 96:3473–9.

23). Tarumi T, Martincic D, Thomas A, Janco R, Hudson M, Baxter P, Gailani D. Familial thrombophilia associated with fibrinogen Paris V: Dusart syndrome. Blood. 2000; 96:1191–3.

24). Kim I, Park S, Lee J, et al. Hereditary thrombophilia in Korea. Korean J Med. 1996; 51:732–42.

25). Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gamma R275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis. 2000; 11:293–304.